CalciMedica, Inc. Research and Development Expense
CalciMedica, Inc. (CALC) reported Research and Development Expense of $2.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- CalciMedica, Inc. research and development expense for the quarter ending 2026-06-30 was $2.10M, a 48.12% decline year-over-year.
- CalciMedica, Inc. research and development expense for the quarter ending 2026-03-31 was $3.48M, a 17.50% decline year-over-year.
- CalciMedica, Inc. research and development expense for the quarter ending 2025-12-31 was $3.11M, a 18.90% decline year-over-year.
- CalciMedica, Inc. research and development expense for the quarter ending 2025-09-30 was $3.85M, a 8.60% increase year-over-year.
- CalciMedica, Inc. research and development expense for fiscal 2025 was $15.23M, a 5.22% increase from fiscal 2024.
- CalciMedica, Inc. research and development expense for fiscal 2024 was $14.48M, a 8.71% decline from fiscal 2023.
- CalciMedica, Inc. research and development expense for fiscal 2023 was $15.86M, a 89.93% increase from fiscal 2022.
- CalciMedica, Inc. research and development expense for fiscal 2022 was $8.35M, a 55.83% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.10M 10-Q · filed 2026-08-11 | $5.59M 10-Q · filed 2026-08-11 | $8.69M derived: sum of 3 quarters · filed 2026-08-11 | $12.54M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $3.48M 10-Q · filed 2026-05-12 | $6.59M derived: sum of 2 quarters · filed 2026-05-12 | $10.44M derived: sum of 3 quarters · filed 2026-05-12 | $14.49M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $6.96M derived: sum of 2 quarters · filed 2026-03-03 | $11.01M derived: sum of 3 quarters · filed 2026-08-11 | $15.23M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | $3.85M 10-Q · filed 2025-11-12 | $7.90M derived: sum of 2 quarters · filed 2026-08-11 | $12.13M 10-Q · filed 2025-11-12 | $15.96M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $4.05M 10-Q · filed 2026-08-11 | $8.28M 10-Q · filed 2026-08-11 | $12.11M derived: sum of 3 quarters · filed 2026-08-11 | $15.65M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $4.22M 10-Q · filed 2026-05-12 | $8.05M derived: sum of 2 quarters · filed 2026-05-12 | $11.60M derived: sum of 3 quarters · filed 2026-05-12 | $15.76M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $7.38M derived: sum of 2 quarters · filed 2026-03-03 | $11.53M derived: sum of 3 quarters · filed 2026-03-03 | $14.48M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $3.55M 10-Q · filed 2025-11-12 | $7.70M derived: sum of 2 quarters · filed 2025-11-12 | $10.65M 10-Q · filed 2025-11-12 | $13.43M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $4.16M 10-Q · filed 2025-08-12 | $7.10M 10-Q · filed 2025-08-12 | $9.88M derived: sum of 3 quarters · filed 2025-08-12 | $12.65M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $2.94M 10-Q · filed 2025-05-14 | $5.73M derived: sum of 2 quarters · filed 2025-05-14 | $8.50M derived: sum of 3 quarters · filed 2025-05-14 | $12.31M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $5.55M derived: sum of 2 quarters · filed 2025-03-27 | $9.37M derived: sum of 3 quarters · filed 2025-03-27 | $15.86M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $2.77M 10-Q · filed 2024-11-13 | $6.59M derived: sum of 2 quarters · filed 2024-11-13 | $13.08M 10-Q · filed 2024-11-13 | $15.00M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $3.81M 10-Q · filed 2024-08-12 | $10.30M 10-Q · filed 2024-08-12 | $12.23M derived: sum of 3 quarters · filed 2024-08-12 | $13.47M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $6.49M 10-Q · filed 2024-05-13 | $8.41M derived: sum of 2 quarters · filed 2024-05-13 | $9.66M derived: sum of 3 quarters · filed 2024-05-13 | $11.92M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.17M derived: sum of 2 quarters · filed 2024-03-28 | $5.42M derived: sum of 3 quarters · filed 2024-03-28 | $8.35M 10-K · filed 2024-03-28 | $14.11M 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $1.24M 10-Q · filed 2023-11-09 | $3.25M 10-Q · filed 2022-11-10 | $3.50M derived: sum of 2 quarters · filed 2023-11-09 | $6.43M 10-Q · filed 2023-11-09 | $13.36M 10-Q · filed 2022-11-10 | $10.70M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $2.26M 10-Q · filed 2023-08-11 | $4.06M 10-Q · filed 2022-08-12 | $5.18M 10-Q · filed 2023-08-11 | $10.12M 10-Q · filed 2022-08-12 | $9.45M derived: sum of 3 quarters · filed 2023-08-11 | $13.47M derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $2.92M 10-Q · filed 2023-05-12 | $6.06M 10-Q · filed 2022-05-12 | $7.19M derived: sum of 2 quarters · filed 2023-05-12 | $11.21M derived: sum of 3 quarters · filed 2023-05-12 | $15.38M derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $8.29M derived: sum of 2 quarters · filed 2023-03-09 | $12.46M derived: sum of 3 quarters · filed 2023-03-09 | $18.90M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $4.02M 10-Q · filed 2022-11-10 | $8.19M derived: sum of 2 quarters · filed 2022-11-10 | $14.63M 10-Q · filed 2022-11-10 | $20.12M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $4.17M 10-Q · filed 2022-08-12 | $10.61M 10-Q · filed 2022-08-12 | $16.10M derived: sum of 3 quarters · filed 2022-08-12 | $20.86M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $6.45M 10-Q · filed 2022-05-12 | $11.94M derived: sum of 2 quarters · filed 2022-05-12 | $16.69M derived: sum of 3 quarters · filed 2022-05-12 | $21.32M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $10.24M derived: sum of 2 quarters · filed 2022-03-11 | $14.88M derived: sum of 3 quarters · filed 2022-03-11 | $20.96M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $4.76M 10-Q · filed 2021-11-12 | $9.39M derived: sum of 2 quarters · filed 2021-11-12 | $15.47M 10-Q · filed 2021-11-12 | $23.48M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $4.63M 10-Q · filed 2021-08-12 | $10.72M 10-Q · filed 2021-08-12 | $18.73M derived: sum of 3 quarters · filed 2021-08-12 | $27.13M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $6.08M 10-Q · filed 2021-05-14 | $14.10M derived: sum of 2 quarters · filed 2021-05-14 | $22.50M derived: sum of 3 quarters · filed 2021-05-14 | |||||
| 2019-12-31 | $8.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $16.41M derived: sum of 2 quarters · filed 2021-03-05 | $30.58M 10-K · filed 2021-03-05 | |||||
| 2019-09-30 | $8.40M 10-Q · filed 2020-11-12 | $22.57M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |